AbbVie's Revenue by Segment

In fiscal year 2024, AbbVie's revenue by segment (products & services) are as follows:

Alphagan/Combigan: $248.00M
Botox Cosmetic: $2.72B
Botox Therapeutic: $3.28B
Duodopa: $447.00M
H U M I R A: $8.99B
Imbruvica: $3.35B
Juvederm Collection: $1.18B
Linzess/Constella: $954.00M
Lumigan/Ganfort: $429.00M
MAVYRET: $1.31B
Other Aesthetics: $1.28B
Other Eye Care: $847.00M
Other Neuroscience: $338.00M
Other Products: $3.03B
Ozurdex: $494.00M
Qulipta: $658.00M
Restasis: $224.00M
RINVOQ: $5.97B
SKYRIZI: $11.72B
Ubrelvy: $1.01B
VENCLEXTA: $2.58B
Vraylar: $3.27B

Learn more about AbbVie’s Revenue by Geography

Check out competitors to AbbVie in a side-by-side comparison.

Explore additional financial metrics for AbbVie.


Alphagan/Combigan	346000000
Botox Cosmetic	2615000000
Botox Therapeutic	2719000000
Duodopa	458000000
H U M I R A	21237000000
Imbruvica	4568000000
Juvederm Collection	1428000000
Linzess/Constella	1035000000
Lumigan/Ganfort	514000000
MAVYRET	1541000000
Other Aesthetics	1290000000
Other Eye Care	1175000000
Other Neuroscience	475000000
Other Products	4137000000
Restasis	666000000
RINVOQ	2522000000
SKYRIZI	5165000000
VENCLEXTA	2009000000
Vraylar	2038000000


Alphagan/Combigan	272000000
Botox Cosmetic	2682000000
Botox Therapeutic	2991000000
Duodopa	468000000
H U M I R A	14404000000
Imbruvica	3596000000
Juvederm Collection	1378000000
Linzess/Constella	1108000000
Lumigan/Ganfort	432000000
MAVYRET	1430000000
Other Aesthetics	1234000000
Other Eye Care	803000000
Other Neuroscience	276000000
Other Products	3035000000
Ozurdex	472000000
Qulipta	408000000
Restasis	436000000
RINVOQ	3969000000
SKYRIZI	7763000000
Ubrelvy	815000000
VENCLEXTA	2288000000
Vraylar	2759000000


Alphagan/Combigan	248000000
Botox Cosmetic	2720000000
Botox Therapeutic	3283000000
Duodopa	447000000
H U M I R A	8993000000
Imbruvica	3347000000
Juvederm Collection	1177000000
Linzess/Constella	954000000
Lumigan/Ganfort	429000000
MAVYRET	1311000000
Other Aesthetics	1279000000
Other Eye Care	847000000
Other Neuroscience	338000000
Other Products	3032000000
Ozurdex	494000000
Qulipta	658000000
Restasis	224000000
RINVOQ	5971000000
SKYRIZI	11718000000
Ubrelvy	1006000000
VENCLEXTA	2583000000
Vraylar	3267000000

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2022, AbbVie's revenue by segment is as follows:

Alphagan/Combigan generated $346.00M in revenue, representing 0.62% of its total revenue.
Botox Cosmetic generated $2.62B in revenue, representing 4.67% of its total revenue.
Botox Therapeutic generated $2.72B in revenue, representing 4.86% of its total revenue.
Duodopa generated $458.00M in revenue, representing 0.82% of its total revenue.
H U M I R A generated $21.24B in revenue, representing 37.97% of its total revenue.
Imbruvica generated $4.57B in revenue, representing 8.17% of its total revenue.
Juvederm Collection generated $1.43B in revenue, representing 2.55% of its total revenue.
Linzess/Constella generated $1.04B in revenue, representing 1.85% of its total revenue.
Lumigan/Ganfort generated $514.00M in revenue, representing 0.92% of its total revenue.
MAVYRET generated $1.54B in revenue, representing 2.75% of its total revenue.
Other Aesthetics generated $1.29B in revenue, representing 2.31% of its total revenue.
Other Eye Care generated $1.18B in revenue, representing 2.1% of its total revenue.
Other Neuroscience generated $475.00M in revenue, representing 0.85% of its total revenue.
Other Products generated $4.14B in revenue, representing 7.4% of its total revenue.
Restasis generated $666.00M in revenue, representing 1.19% of its total revenue.
RINVOQ generated $2.52B in revenue, representing 4.51% of its total revenue.
SKYRIZI generated $5.17B in revenue, representing 9.23% of its total revenue.
VENCLEXTA generated $2.01B in revenue, representing 3.59% of its total revenue.
Vraylar generated $2.04B in revenue, representing 3.64% of its total revenue.

The biggest segment for AbbVie is the H U M I R A, which represents 37.97% of its total revenue.
The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.62% of its total revenue.

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2023, AbbVie's revenue by segment is as follows:

Alphagan/Combigan generated $272.00M in revenue, representing 0.51% of its total revenue.
Botox Cosmetic generated $2.68B in revenue, representing 5.06% of its total revenue.
Botox Therapeutic generated $2.99B in revenue, representing 5.64% of its total revenue.
Duodopa generated $468.00M in revenue, representing 0.88% of its total revenue.
H U M I R A generated $14.40B in revenue, representing 27.17% of its total revenue.
Imbruvica generated $3.60B in revenue, representing 6.78% of its total revenue.
Juvederm Collection generated $1.38B in revenue, representing 2.6% of its total revenue.
Linzess/Constella generated $1.11B in revenue, representing 2.09% of its total revenue.
Lumigan/Ganfort generated $432.00M in revenue, representing 0.81% of its total revenue.
MAVYRET generated $1.43B in revenue, representing 2.7% of its total revenue.
Other Aesthetics generated $1.23B in revenue, representing 2.33% of its total revenue.
Other Eye Care generated $803.00M in revenue, representing 1.51% of its total revenue.
Other Neuroscience generated $276.00M in revenue, representing 0.52% of its total revenue.
Other Products generated $3.04B in revenue, representing 5.72% of its total revenue.
Ozurdex generated $472.00M in revenue, representing 0.89% of its total revenue.
Qulipta generated $408.00M in revenue, representing 0.77% of its total revenue.
Restasis generated $436.00M in revenue, representing 0.82% of its total revenue.
RINVOQ generated $3.97B in revenue, representing 7.49% of its total revenue.
SKYRIZI generated $7.76B in revenue, representing 14.64% of its total revenue.
Ubrelvy generated $815.00M in revenue, representing 1.54% of its total revenue.
VENCLEXTA generated $2.29B in revenue, representing 4.32% of its total revenue.
Vraylar generated $2.76B in revenue, representing 5.2% of its total revenue.

The biggest segment for AbbVie is the H U M I R A, which represents 27.17% of its total revenue.
The smallest segment for AbbVie is the Alphagan/Combigan, which represents 0.51% of its total revenue.

The above chart shows AbbVie's revenue percentage share by segment (products and services).

In fiscal year 2024, AbbVie's revenue by segment is as follows:

Alphagan/Combigan generated $248.00M in revenue, representing 0.46% of its total revenue.
Botox Cosmetic generated $2.72B in revenue, representing 5.01% of its total revenue.
Botox Therapeutic generated $3.28B in revenue, representing 6.04% of its total revenue.
Duodopa generated $447.00M in revenue, representing 0.82% of its total revenue.
H U M I R A generated $8.99B in revenue, representing 16.55% of its total revenue.
Imbruvica generated $3.35B in revenue, representing 6.16% of its total revenue.
Juvederm Collection generated $1.18B in revenue, representing 2.17% of its total revenue.
Linzess/Constella generated $954.00M in revenue, representing 1.76% of its total revenue.
Lumigan/Ganfort generated $429.00M in revenue, representing 0.79% of its total revenue.
MAVYRET generated $1.31B in revenue, representing 2.41% of its total revenue.
Other Aesthetics generated $1.28B in revenue, representing 2.35% of its total revenue.
Other Eye Care generated $847.00M in revenue, representing 1.56% of its total revenue.
Other Neuroscience generated $338.00M in revenue, representing 0.62% of its total revenue.
Other Products generated $3.03B in revenue, representing 5.58% of its total revenue.
Ozurdex generated $494.00M in revenue, representing 0.91% of its total revenue.
Qulipta generated $658.00M in revenue, representing 1.21% of its total revenue.
Restasis generated $224.00M in revenue, representing 0.41% of its total revenue.
RINVOQ generated $5.97B in revenue, representing 10.99% of its total revenue.
SKYRIZI generated $11.72B in revenue, representing 21.57% of its total revenue.
Ubrelvy generated $1.01B in revenue, representing 1.85% of its total revenue.
VENCLEXTA generated $2.58B in revenue, representing 4.75% of its total revenue.
Vraylar generated $3.27B in revenue, representing 6.01% of its total revenue.

The biggest segment for AbbVie is the SKYRIZI, which represents 21.57% of its total revenue.
The smallest segment for AbbVie is the Restasis, which represents 0.41% of its total revenue.

Summary Table

Products & Services (Percent Share)	2022	2023	2024
VENCLEXTA	3.59%	4.32%	4.75%
Imbruvica	8.17%	6.78%	6.16%
Restasis	1.19%	0.82%	0.41%
Other Eye Care	2.1%	1.51%	1.56%
Lumigan/Ganfort	0.92%	0.81%	0.79%
Alphagan/Combigan	0.62%	0.51%	0.46%
Other Aesthetics	2.31%	2.33%	2.35%
Juvederm Collection	2.55%	2.6%	2.17%
Botox Cosmetic	4.67%	5.06%	5.01%
MAVYRET	2.75%	2.7%	2.41%
H U M I R A	37.97%	27.17%	16.55%
RINVOQ	4.51%	7.49%	10.99%
SKYRIZI	9.23%	14.64%	21.57%
Botox Therapeutic	4.86%	5.64%	6.04%
Duodopa	0.82%	0.88%	0.82%
Other Neuroscience	0.85%	0.52%	0.62%
Vraylar	3.64%	5.2%	6.01%
Linzess/Constella	1.85%	2.09%	1.76%
Other Products	7.4%	5.72%	5.58%
Ubrelvy	-	1.54%	1.85%
Ozurdex	-	0.89%	0.91%
Qulipta	-	0.77%	1.21%
Total Revenue	100%	100%	100%

The above chart shows the revenue trend of different segments of AbbVie.

In fiscal year 2024, the SKYRIZI generated the most revenue ($11.72B), and the Restasis generated the least revenue ($224.00M).

The above chart shows growth drivers and a year-over-year comparison of different segments' revenue.

Alphagan/Combigan revenue decreased -8.82% ($24.00M) from $272.00M (in 2023) to $248.00M (in 2024).

Botox Cosmetic revenue increased 1.42% ($38.00M) from $2.68B (in 2023) to $2.72B (in 2024).

Botox Therapeutic revenue increased 9.76% ($292.00M) from $2.99B (in 2023) to $3.28B (in 2024).

Duodopa revenue decreased -4.49% ($21.00M) from $468.00M (in 2023) to $447.00M (in 2024).

H U M I R A revenue decreased -37.57% ($5.41B) from $14.40B (in 2023) to $8.99B (in 2024).

Imbruvica revenue decreased -6.92% ($249.00M) from $3.60B (in 2023) to $3.35B (in 2024).

Juvederm Collection revenue decreased -14.59% ($201.00M) from $1.38B (in 2023) to $1.18B (in 2024).

Linzess/Constella revenue decreased -13.9% ($154.00M) from $1.11B (in 2023) to $954.00M (in 2024).

Lumigan/Ganfort revenue decreased -0.69% ($3.00M) from $432.00M (in 2023) to $429.00M (in 2024).

MAVYRET revenue decreased -8.32% ($119.00M) from $1.43B (in 2023) to $1.31B (in 2024).

Other Aesthetics revenue increased 3.65% ($45.00M) from $1.23B (in 2023) to $1.28B (in 2024).

Other Eye Care revenue increased 5.48% ($44.00M) from $803.00M (in 2023) to $847.00M (in 2024).

Other Neuroscience revenue increased 22.46% ($62.00M) from $276.00M (in 2023) to $338.00M (in 2024).

Other Products revenue decreased -0.1% ($3.00M) from $3.04B (in 2023) to $3.03B (in 2024).

Ozurdex revenue increased 4.66% ($22.00M) from $472.00M (in 2023) to $494.00M (in 2024).

Qulipta revenue increased 61.27% ($250.00M) from $408.00M (in 2023) to $658.00M (in 2024).

Restasis revenue decreased -48.62% ($212.00M) from $436.00M (in 2023) to $224.00M (in 2024).

RINVOQ revenue increased 50.44% ($2.00B) from $3.97B (in 2023) to $5.97B (in 2024).

SKYRIZI revenue increased 50.95% ($3.96B) from $7.76B (in 2023) to $11.72B (in 2024).

Ubrelvy revenue increased 23.44% ($191.00M) from $815.00M (in 2023) to $1.01B (in 2024).

VENCLEXTA revenue increased 12.89% ($295.00M) from $2.29B (in 2023) to $2.58B (in 2024).

Vraylar revenue increased 18.41% ($508.00M) from $2.76B (in 2023) to $3.27B (in 2024).

Summary Table

Products & Services	2022 Value Change	2023 Value Change	2024 Value Change
Alphagan/Combigan	$346.00M -	$272.00M 21.39%	$248.00M 8.82%
Botox Cosmetic	$2.62B -	$2.68B 2.56%	$2.72B 1.42%
Botox Therapeutic	$2.72B -	$2.99B 10.00%	$3.28B 9.76%
Duodopa	$458.00M -	$468.00M 2.18%	$447.00M 4.49%
H U M I R A	$21.24B -	$14.40B 32.17%	$8.99B 37.57%
Imbruvica	$4.57B -	$3.60B 21.28%	$3.35B 6.92%
Juvederm Collection	$1.43B -	$1.38B 3.50%	$1.18B 14.59%
Linzess/Constella	$1.04B -	$1.11B 7.05%	$954.00M 13.90%
Lumigan/Ganfort	$514.00M -	$432.00M 15.95%	$429.00M 0.69%
MAVYRET	$1.54B -	$1.43B 7.20%	$1.31B 8.32%
Other Aesthetics	$1.29B -	$1.23B 4.34%	$1.28B 3.65%
Other Eye Care	$1.18B -	$803.00M 31.66%	$847.00M 5.48%
Other Neuroscience	$475.00M -	$276.00M 41.89%	$338.00M 22.46%
Other Products	$4.14B -	$3.04B 26.64%	$3.03B 0.10%
Ozurdex	- -	$472.00M -	$494.00M 4.66%
Qulipta	- -	$408.00M -	$658.00M 61.27%
Restasis	$666.00M -	$436.00M 34.53%	$224.00M 48.62%
RINVOQ	$2.52B -	$3.97B 57.38%	$5.97B 50.44%
SKYRIZI	$5.17B -	$7.76B 50.30%	$11.72B 50.95%
Ubrelvy	- -	$815.00M -	$1.01B 23.44%
VENCLEXTA	$2.01B -	$2.29B 13.89%	$2.58B 12.89%
Vraylar	$2.04B -	$2.76B 35.38%	$3.27B 18.41%
Total Revenue	$55.94B -	$53.02B 5.22%	$54.33B 2.47%

AbbVie's Revenue by Segment

Summary Table

Summary Table

Related company

Submit feedback to Bullfincher